Literature DB >> 21595793

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.

O Zarkotou1, S Pournaras, P Tselioti, V Dragoumanos, V Pitiriga, K Ranellou, A Prekates, K Themeli-Digalaki, A Tsakris.   

Abstract

Bloodstream infections (BSIs) caused by Klebsiella pneumoniae carbapenemases (KPC)-producing K. pneumoniae (KPC-KP) are associated with high mortality rates. We investigated outcomes, risk factors for mortality and impact of appropriate antimicrobial treatment in patients with BSIs caused by molecularly confirmed KPC-KP. All consecutive patients with KPC-KP BSIs between May 2008 and May 2010 were included in the study and followed-up until their discharge or death. Potential risk factors for infection mortality were examined by a case-control study. Case-patients were those who died from the BSI and control-patients those who survived. Appropriate antimicrobial therapy was defined as treatment with in vitro active antimicrobials for at least 48 h. A total of 53 patients were identified. Overall mortality was 52.8% and infection mortality was 34%. Appropriate antimicrobial therapy was administered to 35 patients; mortality due to infection occurred in 20%. All 20 patients that received combination schemes had favourable infection outcome; in contrast, seven of 15 patients given appropriate monotherapy died (p 0.001). In univariate analysis, risk factors for mortality were age (p <0.001), APACHE II score at admission and infection onset (p <0.001) and severe sepsis (p <0.001), while appropriate antimicrobial treatment (p 0.003), combinations of active antimicrobials (p 0.001), catheter-related bacteraemia (p 0.04), prior surgery (p 0.014) and other therapeutic interventions (p 0.015) were significantly associated with survival. Independent predictors of mortality were age, APACHE II score at infection onset and inappropriate antimicrobial treatment. Among them, appropriate treatment is the only modifiable independent predictor of infection outcome.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595793     DOI: 10.1111/j.1469-0691.2011.03514.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  156 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination.

Authors:  Aggeliki Poulou; Evangelia Voulgari; Georgia Vrioni; Grigorios Xidopoulos; Aris Pliagkos; Vassiliki Chatzipantazi; Fani Markou; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

Review 3.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

4.  Population Structure of Klebsiella pneumoniae Causing Bloodstream Infections at a New York City Tertiary Care Hospital: Diversification of Multidrug-Resistant Isolates.

Authors:  Angela Gomez-Simmonds; Michelle Greenman; Sean B Sullivan; Joshua P Tanner; Madeleine G Sowash; Susan Whittier; Anne-Catrin Uhlemann
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 5.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation.

Authors:  A Forcina; R Baldan; V Marasco; P Cichero; A Bondanza; M Noviello; S Piemontese; C Soliman; R Greco; F Lorentino; F Giglio; C Messina; M Carrabba; M Bernardi; J Peccatori; M Moro; A Biancardi; P Nizzero; P Scarpellini; D M Cirillo; N Mancini; C Corti; M Clementi; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

7.  Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.

Authors:  Alessandro Russo; Simone Giuliano; Giancarlo Ceccarelli; Francesco Alessandri; Alessandra Giordano; Grazia Brunetti; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2014-12-09       Impact factor: 5.790

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.